Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats
ConclusionHCTZ reduces tolvaptan-induced polyuria without altering its beneficial effects on PKD. This novel therapeutic combination could potentially lead to better PKD treatments and improved quality of life for the affected patients.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
More News: Brain | Diabetes | Diabetes Insipidus | Endocrinology | Hydrochlorothiazide | Neurology | Polycystic Kidney Disease | Study | Urology & Nephrology